Table 2.
Insulin (N=21) | Placebo (N=24) | p value | |||
---|---|---|---|---|---|
Adverse event | N | % | N | % | |
Wheezing | 2 | 10 | 0 | 0 | 0.41 |
Coughing | 2 | 10 | 0 | 0 | 0.41 |
Trouble breathing | 1 | 5 | 0 | 0 | 1.00 |
Nasal congestion | 2 | 10 | 1 | 4 | 0.92 |
Hypersalivation | 1 | 5 | 0 | 0 | 1.00 |
Nausea | 1 | 5 | 0 | 0 | 1.00 |
Vomiting | 1 | 5 | 0 | 0 | 1.00 |
Numbness | 1 | 5 | 0 | 0 | 1.00 |
Poor concentration | 2 | 10 | 1 | 4 | 0.92 |
Confusion | 1 | 5 | 0 | 0 | 1.00 |
Insomnia | 4 | 19 | 0 | 0 | 0.09 |
Drowsiness | 2 | 10 | 0 | 0 | 0.92 |
occurred in more than 5% of the subjects taking insulin and was at least twice as common as in the placebo group.